- Home
- FGEN vs CCEL Comparison
FGEN vs CCEL Comparison
Compare FGEN & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- CCEL
- Stock Information
- Founded
- FGEN 1993
- CCEL 1989
- Country
- FGEN United States
- CCEL United States
- Employees
- FGEN N/A
- CCEL N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- FGEN Health Care
- CCEL Health Care
- Exchange
- FGEN Nasdaq
- CCEL Nasdaq
- Market Cap
- FGEN 38.4M
- CCEL 39.9M
- IPO Year
- FGEN 2014
- CCEL 1997
- Fundamental
- Price
- FGEN $10.56
- CCEL $4.44
- Analyst Decision
- FGEN Strong Buy
- CCEL Strong Buy
- Analyst Count
- FGEN 2
- CCEL 1
- Target Price
- FGEN $146.50
- CCEL $8.50
- AVG Volume (30 Days)
- FGEN 66.4K
- CCEL 9.1K
- Earning Date
- FGEN 08-11-2025
- CCEL 10-14-2025
- Dividend Yield
- FGEN N/A
- CCEL 13.88%
- EPS Growth
- FGEN N/A
- CCEL N/A
- EPS
- FGEN N/A
- CCEL N/A
- Revenue
- FGEN $7,346,000.00
- CCEL $31,988,783.00
- Revenue This Year
- FGEN N/A
- CCEL $1.75
- Revenue Next Year
- FGEN N/A
- CCEL N/A
- P/E Ratio
- FGEN N/A
- CCEL N/A
- Revenue Growth
- FGEN N/A
- CCEL 1.10
- 52 Week Low
- FGEN $4.50
- CCEL $4.09
- 52 Week High
- FGEN $21.94
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- FGEN 68.96
- CCEL 43.35
- Support Level
- FGEN $9.05
- CCEL $4.23
- Resistance Level
- FGEN $11.71
- CCEL $4.70
- Average True Range (ATR)
- FGEN 0.77
- CCEL 0.22
- MACD
- FGEN 0.32
- CCEL -0.07
- Stochastic Oscillator
- FGEN 76.95
- CCEL 26.01
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.